SCHEMBL17446923

SCHEMBL17446923

C=C1C[C@@H](C)C(c2ccc(NC(C)=O)c(Cl)c2)=NN1

nearest known ligand 0.78

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ PDE3B Q13370 7/20 0.78
▸ PDE3A Q14432 7/20 0.78
▸ SMN1; SMN2 Q16637 2/20 0.43
▸ ALDH1A1 P00352 2/20 0.43
▸ KDM4E B2RXH2 1/20 0.43
▸ CA1 P00915 1/20 0.39
▸ CA2 P00918 1/20 0.39
▸ CA9 Q16790 1/20 0.39
▸ MAPT P10636 2/20 0.39
▸ GALR3 O60755 1/20 0.39
▸ PDE4A P27815 1/20 0.38
▸ PDE4B Q07343 1/20 0.38
▸ PDE4C Q08493 1/20 0.38
▸ PDE4D Q08499 1/20 0.38
▸ GPR119 Q8TDV5 2/20 0.36
▸ ABL1 P00519 3/20 0.36
▸ MOK Q9UQ07 2/20 0.36
▸ NPC1 O15118 1/20 0.36
▸ POLB P06746 1/20 0.36
▸ RAB9A P51151 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17446966 0.87 PDE3B (0.59) PDE3BPDE3ASMN1; SMN2ALDH1A1KDM4E
SCHEMBL16157202 0.87 PDE3B (1.00) PDE3BPDE3ASMN1; SMN2ALDH1A1KDM4E
SCHEMBL16156973 0.87 PDE3B (1.00) PDE3BPDE3ASMN1; SMN2ALDH1A1KDM4E
SCHEMBL17446921 0.86 PDE3B (0.58) PDE3BPDE3ASMN1; SMN2ALDH1A1KDM4E
SCHEMBL17446941 0.86 PDE3B (0.61) PDE3BPDE3ASMN1; SMN2ALDH1A1KDM4E
SCHEMBL17446948 0.84 PDE3B (0.55) PDE3BPDE3ASMN1; SMN2ALDH1A1KDM4E
SCHEMBL17446938 0.83 MAPT (0.56) PDE3BPDE3ASMN1; SMN2ALDH1A1KDM4E
SCHEMBL17446956 0.81 PDE3B (0.74) PDE3BPDE3ASMN1; SMN2ALDH1A1KDM4E
SCHEMBL17446931 0.80 PDE3B (0.70) PDE3BPDE3AMAPTGALR3PDE4A
SCHEMBL17446974 0.80 PDE3B (0.51) PDE3BPDE3ASMN1; SMN2ALDH1A1KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9890127-B2 Compounds and compositions for the treatment of cancer THE BROAD INSTITUTE, INC. (US) 2018-02-13 — — US disclosed
US-20160016913-A1 COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF CANCER THE BROAD INSTITUTE, INC. (US) 2016-01-21 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160016913-A1 COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF CANCER TP53, RB1, CDK4 PDE3B 2667/4885PDE3A 2661/4885SMN1; SMN2 3132/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback